Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.JHP Pharmaceuticals and SpePharm Holding have closed an asset purchase agreement, pursuant to which they have acquired global rights to Procter and Gamble's Dantrium product.
Subscribe to our email newsletter
In its intravenous form, Dantrium is used to treat malignant hyperthermia and in its oral form, the control of clinical spasticity resulting from upper motor neuron disorders (spinal cord injury, stroke, cerebral palsy, or multiple sclerosis).
JHP Pharmaceuticals acquired the rights to Dantrium for the US and Canada, including supply rights in Australia, New Zealand, Israel and Chile while SpePharm Holding acquired the rights in the rest of the world.
Stuart Hinchen, president of JHP, said: “We are delighted to acquire the rights to Dantrium. This product will fit well into our current portfolio of marketed products which already includes exports to Canada and Australia.”
Jean-Francois Labbe, CEO of SpePharm, said: “We have been pleased to partner with JHP in this acquisition and secure Procter and Gamble’s rights to Dantrium in the rest of the world (excluding the JHP territories). In Europe Dantrium will receive support from SpePharm’s growing hospital sales and marketing infrastructure.”